Magazine Article | January 4, 2021

Companies To Watch: Artax Biopharma

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.

SNAPSHOT

Artax Biopharma is a private, early-stage company in preclinical development of its lead drug to treat autoimmunity via a new pathway, Nck (non-catalytic region of tyrosine kinase adaptor protein 1). Coded AX-158, the drug is one of many molecules the company has built to inhibit Nck and thereby modulate T cell-regulated immunity without immunosuppression. AX-158 will enter clinical trials in 2021. More compounds in the AX-100, -300, and -400 series may serve as backups or additional autoimmune treatments in the future.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: